Related Experiment Video
Updated: Sep 26, 2025
08:16
One-anastomosis Gastric Bypass OAGB in Rats
Published on: November 10, 2018
11.1K
Severe post-gastric bypass hypoglycemia in pregnancy
Tal Schiller1, Alena Kirzhner1, Taiba Zornitzki1
1Diabetes, Endocrinology and Metabolic Disease Institute, Kaplan Medical Center, Rehovot, Israel, and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Obesity Research & Clinical Practice
|April 23, 2022
Summary
Post-bariatric surgery hypoglycemia (PBH) is a serious complication. This case highlights the challenges of managing severe PBH during pregnancy, requiring intravenous glucose for treatment.
Area of Science:
- Endocrinology
- Gastroenterology
- Obstetrics
Background:
- Post-bariatric surgery hypoglycemia (PBH) is an underdiagnosed complication.
- Limited data exist on PBH management during pregnancy.
Observation:
- A 34-year-old woman with a history of Roux-en-Y gastric bypass (RYGB) presented with severe hypoglycemia in her third pregnancy.
- Nifedipine provided only partial relief for her intractable PBH.
Findings:
- Intractable PBH during pregnancy poses significant management challenges.
- Intravenous glucose infusion was necessary until delivery to manage severe hypoglycemia.
Implications:
- This case underscores the need for increased awareness and specialized management protocols for PBH in pregnant patients.
- Further research is crucial to establish effective treatment guidelines for PBH during gestation.
Related Concept Videos
01:15Hypoglycemia and Glucagon
362
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
362
01:20Pathophysiology of Diabetes
1.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
289
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
289
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
318
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
318
01:23Dipeptidyl Peptidase 4 Inhibitors
272
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
272